Menu

BeyondSPX has rebranded as EveryTicker. We now operate at everyticker.com, reflecting our coverage across nearly all U.S. tickers. BeyondSPX has rebranded as EveryTicker.

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (12)

Company Market Cap Price
NVO Novo Nordisk A/S
At-home administration devices (auto-injector devices) for GLP-1 therapies are part of Novo Nordisk’s delivery platform.
$172.05B
$38.85
+0.35%
TAK Takeda Pharmaceutical Company Limited
ENTYVIO Pen demonstrates the use of auto-injector devices for at-home administration of biologics.
$56.89B
$18.12
-0.49%
BDX Becton, Dickinson and Company
BD develops auto‑injector devices (wearable injectors) for home/at‑home administration of biologics.
$46.77B
$163.15
-0.45%
ROIV Roivant Sciences Ltd.
Auto-injector devices enabling at-home administration for IMVT-1402, fitting Auto-Injector Devices.
$20.66B
$29.59
-0.39%
WST West Pharmaceutical Services, Inc.
Auto-Injector Devices are a key product category in West's GLP-1 and other injectable platforms.
$16.82B
$238.31
+1.92%
ATR AptarGroup, Inc.
Aptar has auto-injector devices/platforms for at-home administration of injectable therapies.
$8.67B
$132.10
-0.02%
HALO Halozyme Therapeutics, Inc.
Halozyme is expanding its portfolio of auto-injector devices to enable at-home/self-administration of therapies.
$7.97B
$66.48
-1.96%
STVN Stevanato Group S.p.A.
Develops and manufactures Auto-Injector Devices for at-home/self-administration of injectable therapies.
$4.56B
$15.19
+0.80%
AMRX Amneal Pharmaceuticals, Inc.
DHE autoinjector (Brekiya) approval signals involvement in auto-injector device delivery systems.
$4.20B
$12.70
-4.87%
KE Kimball Electronics, Inc.
Auto-injector devices represent a differentiated medical device assembly capability.
$558.81M
$23.14
+0.78%
SCPH scPharmaceuticals Inc.
Auto-Injector Devices reflect the SCP-111 autoinjector program for at-home administration.
$299.33M
$5.67
ASRT Assertio Holdings, Inc.
Otrexup is an auto-injector device, fitting the Auto-Injector Devices category.
$74.62M
$11.50
-1.12%

Loading company comparison...

Loading research report...

NVO Novo Nordisk A/S

Novo Nordisk Receives FDA Warning Letter Over Post‑Marketing Adverse Event Reporting Violations

Mar 11, 2026
WST West Pharmaceutical Services, Inc.

West Pharmaceutical Services CEO Eric Green Announces Retirement

Mar 10, 2026
NVO Novo Nordisk A/S

Novo Nordisk and Hims & Hers Resolve Legal Dispute, Announce Co‑Sell Partnership for Obesity Drugs

Mar 08, 2026
HALO Halozyme Therapeutics, Inc.

FDA Approves TECVAYLI®/DARZALEX FASPRO® Combination for Relapsed or Refractory Multiple Myeloma

Mar 06, 2026
BDX Becton, Dickinson and Company

BD Secures CE Mark for Revello Vascular Covered Stent, Expanding EU Presence

Mar 05, 2026
TAK Takeda Pharmaceutical Company Limited

Takeda to Cut 400 U.S. Jobs Ahead of CEO Transition

Mar 05, 2026
STVN Stevanato Group S.p.A.

Stevanato Group Reports Q4 2025 Earnings Beat, Highlights Growth in High‑Value Solutions

Mar 04, 2026
TAK Takeda Pharmaceutical Company Limited

Takeda and Protagonist Secure FDA Acceptance and Priority Review for Rusfertide

Mar 03, 2026
BDX Becton, Dickinson and Company

Becton, Dickinson Secures FDA Clearance for 1000‑mL Surgiphor Surgical Irrigation System

Mar 02, 2026
NVO Novo Nordisk A/S

Novo Nordisk Invests €432 Million in Athlone Plant to Expand Wegovy Pill Production

Mar 02, 2026
NVO Novo Nordisk A/S

Novo Nordisk Receives FDA Approval for Three New Pediatric Indications for Sogroya

Feb 28, 2026
AMRX Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals Reports Q4 2025 Earnings: EPS Beat, Revenue Missed Estimates

Feb 27, 2026
NVO Novo Nordisk A/S

Novo Nordisk and Vivtex Announce $2.1 B Partnership to Advance Oral Biologics for Obesity and Diabetes

Feb 25, 2026
NVO Novo Nordisk A/S

Novo Nordisk’s CagriSema Trial Fails to Meet Non‑Inferiority to Eli Lilly’s Tirzepatide

Feb 23, 2026
TAK Takeda Pharmaceutical Company Limited

Takeda Secures Pediatric Ulcerative Colitis Approval for ENTYVIO After Positive Phase 3 Results

Feb 19, 2026
WST West Pharmaceutical Services, Inc.

West Pharmaceutical Services Authorizes $1 Billion Share Repurchase Program

Feb 18, 2026
NVO Novo Nordisk A/S

Novo Nordisk Gains EU Approval for 7.2 mg Wegovy Dose, Expanding Treatment Options

Feb 17, 2026
NVO Novo Nordisk A/S

Novo Nordisk Announces DKK 15 Billion Share Repurchase Programme for B Shares

Feb 16, 2026
NVO Novo Nordisk A/S

Novo Nordisk to Launch Wegovy Vials, Expanding Distribution Options

Feb 12, 2026
WST West Pharmaceutical Services, Inc.

West Pharmaceutical Services Reports Strong Q4 2025 Results, Raises 2026 Guidance

Feb 12, 2026
BDX Becton, Dickinson and Company

Becton, Dickinson Launches $1.6 Billion Debt Tender Offer to Reduce Leverage

Feb 11, 2026
TAK Takeda Pharmaceutical Company Limited

Takeda Secures FDA Acceptance and Priority Review for Oveporexton, a First‑in‑Class Orexin Agonist

Feb 10, 2026